Cornerstone BioPharma, Inc and SJ Pharmaceuticals, LLC Sign Co-Promotion Agreement

Released on = July 9, 2007, 2:07 pm

Press Release Author = Rachel Wells, 919 Marketing

Industry = Pharmaceuticals

Press Release Summary = Cornerstone BioPharmaT, the Triangle-based specialty
pharmaceutical company currently focused on the development and commercialization of
niche prescription medications in the respiratory arena, today announced it has
signed a co-promotion agreement with SJ Pharmaceuticals (SJP).

Press Release Body = FOR IMMEDIATE RELEASE


CARY, NORTH CAROLINA - July 9, 2007- Cornerstone BioPharmaT, the Triangle-based
specialty pharmaceutical company currently focused on the development and
commercialization of niche prescription medications in the respiratory arena, today
announced it has signed a co-promotion agreement with SJ Pharmaceuticals (SJP).
This agreement names SJP as a partner in the promotion of Spectracef®, a broad
spectrum, third-generation cephalosporin.


Essentially, when a patient is diagnosed with a bacterial infection, Spectracef® is
used to help the body fight off pathogens. It is an oral antibiotic used to treat
such things as Community-Acquired Pneumonia (CAP), Acute Bacterial Exacerbation of
Chronic Bronchitis (ABECB), Pharyngitis/Tonsillitis, and Uncomplicated Skin and
Skin-Structure Infections (USSSI). Spectracef®, a part of the major therapeutic
category of antibiotics, will be beneficial to most primary care physicians as the
discovery and development of new antibiotics becomes more valuable in the medical
field.


Cornerstone obtained exclusive U.S. licensing rights for Spectracef® from leading
Japanese pharmaceutical company Meiji Seika Kaisha in October 2006 and began
promotion through their sales force shortly thereafter. Commencing immediately, the
SJ Pharmaceuticals sales force will co-promote Spectracef®, significantly increasing
awareness, promotional efforts and reach of the medication. The total worldwide
market for antibiotic treatments was $25 billion in 2005, with $4.7 billion
allocated to the respiratory antibiotic market. Cornerstone's new partnership with
SJP represents expansion into the $1.5 billion U.S. oral solid cephalosporin market
and will serve to increase the recognition of Spectacef® among healthcare providers.

Commenting on the agreement, SJ Pharmaceuticals President Terri Jackson Wade said,
"Spectracef is a proven cephalosporin antibiotic with, we believe, untapped
potential. The SJP sales team has tremendous depth in the respiratory category and
the Southeast, and we are thrilled to be leveraging our credibility and expertise in
this partnership with Cornerstone BioPharma."


\"SJP's experienced sales force is well entrenched in the market and will allow us to
reach more healthcare providers. There is a strong need for antibiotic options in
light of the resistance issues faced by today's healthcare community. With SJP's
sales force, more practitioners will learn about Spectracef® as a highly potent
option for respiratory and skin diseases,\" said Craig Collard, President and CEO of
Cornerstone BioPharma.




# # #


About Cornerstone
Cornerstone BioPharma, Inc. (www.cornerstonebiopharma.com), located next to North
Carolina's Research Triangle Park, is an emerging specialty pharmaceutical company
that is currently focused on the development and commercialization of niche
prescription medications in the respiratory arena. Cornerstone is actively engaged
in strategic licensing of additional prescription products through acquisitions,
strategic partnerships and new product development.



About SJ Pharmaceuticals
SJ Pharmaceuticals, LLC (www.sjpharma.com), is a dynamic family business committed
to the development and marketing of prescription pharmaceutical products. With
products in the respiratory, urology, and cardiovascular therapeutic categories, SJP
actively seeks to advance treatment options for providers and their patients through
the commercialization of innovative yet practical pharmaceutical products. SJP
continues to build on its 30 plus year heritage as it cultivates a premier sales and
marketing organization.








Web Site = www.cornerstonebiopharma.com

Contact Details = Rachel Wells
919 Marketing
919-459-8161
rwells@919marketing.com

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •